SRTA on Nasdaq
Strata Critical Medical, Inc.
American health services company, incorporated in Delaware1
In its 2026 annual report the company says: “The Company operates one of the nation’s largest air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated “one call” solution for donor organ recovery.”4 It is headquartered in New York, New York.1 Its shares trade on Nasdaq under the symbol SRTA.1
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with Omada Health, Inc., DocGo Inc. or GeneDx Holdings Corp., or pick any stock.
- TickerSRTA on Nasdaq1
- IndustryServices-Health Services1
- HeadquartersNew York, New York1
- Incorporated inDE2
- Business address666 Third Avenue, 25Th Floor, New York, Ny 100172
- Filer categoryAccelerated filer2
See how the biggest companies compare on our leaderboards
Strata Critical Medical, Inc.(f/k/a Blade Air Mobility, Inc.) (“Strata” or the “Company”) is a time-critical logistics and medical services provider to the United States healthcare industry. The Company operates one of the nation’s largest air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated “one call” solution for donor organ recovery. Strata’s core services include air and ground logistics, organ placement, surgical organ recovery, normothermic regional perfusion and preservation for the transplant industry, as well as perfusion staffing and equipment solutions for cardiovascular surgery centers, offered under the Trinity Medical Solutions (“Trinity”) and Keystone Perfusion Services LLC (“Keystone”) brands.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Business segments
Logistics brought in 90% of the revenue Strata Critical Medical, Inc. broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2024 | 2025 |
|---|---|---|
| Logistics | $146.8M | $176.8M |
| Clinical | $0 | $20.3M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue60¢$156.0M
- Selling, general and admin24¢$60.9M
- Profit16¢$41.3M
Out of $197.1M in revenue.5
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | $197.1M | $146.8M |
| Cost of revenue | $156.0M | $117.2M |
| Gross Profit | $41.1M | $29.6M |
| Selling, general and administrative | $60.9M | $50.9M |
| Amortization of intangible assets | $2.6M | $1.3M |
| Total operating expenses | $63.5M | $52.1M |
| Operating loss from continuing operations | -$22.4M | -$22.5M |
| Interest income | $4.2M | $7.2M |
| Change in fair value of warrant liabilities | $4.3M | -$850.0K |
| Change in fair value of assets and other liabilities | -$1.0M | $0 |
| Realized loss from sales of short-term investments | -$5.2M | $0 |
| Total other non-operating income | $2.3M | $6.4M |
| Loss from continuing operations before income taxes | -$20.1M | -$16.2M |
| Income tax expense from continuing operations | $0 | $0 |
| Net loss from continuing operations | -$20.1M | -$16.2M |
| Net income (loss) from discontinued operations | $61.4M | -$11.1M |
| Net income (loss) | $41.3M | -$27.3M |
| Continuing operations, basic (in dollars per share) | -$0 | -$0 |
| Continuing operations , diluted (in dollars per share) | -$0 | -$0 |
| Discontinued operations, basic (in dollars per share) | $1 | -$0 |
| Discontinued operations, diluted (in dollars per share) | $1 | -$0 |
| Total basic earnings (loss) per share (in dollars per share) | $0.50 | -$0.35 |
| Total diluted earnings (loss) per share (in dollars per share) | $0.50 | -$0.35 |
| Basic (in shares) | 82.1M shares | 77.5M shares |
| Diluted (in shares) | 82.1M shares | 77.5M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $31.0M | $16.1M | |
| Restricted cash | $264.0K | $263.0K | |
| Accounts receivable, net of allowance of $1,066 and $ at December 31, 2025 and December 31, 2024, respectively | $40.0M | $19.8M | |
| Short-term investments | $30.3M | $108.8M | |
| Prepaid expenses and other current assets | $24.7M | $4.7M | |
| Current assets of discontinued operations | $0 | $11.2M | |
| Total current assets | $126.2M | $160.7M | |
| Property and equipment, net | $36.4M | $28.5M | |
| Intangible assets, net | $47.5M | $8.0M | |
| Goodwill | $88.2M | $15.5M | $13.3M |
| Operating right-of-use asset | $3.1M | $2.8M | |
| Other non-current assets | $24.0M | $118.0K | |
| Non current assets of discontinued operations | $0 | $41.0M | |
| Total assets | $325.5M | $256.7M | |
| Accounts payable and accrued expenses | $19.1M | $9.2M | |
| Operating lease liability, current | $652.0K | $682.0K | |
| Current liabilities of discontinued operations | $0 | $12.8M | |
| Total current liabilities | $19.8M | $22.7M | |
| Warrant liability | $1.5M | $5.8M | |
| Operating lease liability, long-term | $2.7M | $2.3M | |
| Deferred tax liability | $348.0K | $0 | |
| Other non-current liabilities | $22.1M | $0 | |
| Non-current liabilities of discontinued operations | $0 | $3.9M | |
| Total liabilities | $46.4M | $34.7M | |
| Preferred stock, $0.0001 par value, 2,000,000 shares authorized; no shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $0 | $0 | |
| Common stock, $0.0001 par value; 400,000,000 authorized; 86,702,183 and 79,419,028 shares issued at December 31, 2025 and December 31, 2024, respectively | $7.0K | $7.0K | |
| Additional paid in capital | $424.6M | $407.1M | |
| Accumulated other comprehensive income | $0 | $1.8M | |
| Accumulated deficit | -$145.6M | -$186.9M | |
| Total stockholders' equity | $279.1M | $221.9M | $234.3M |
| Total liabilities and stockholders' equity | $325.5M | $256.7M | |
| Allowance for credit losses | $1.1M | $0 | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 2.0M shares | 2.0M shares | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 400.0M shares | 400.0M shares | |
| Common stock, shares issued (in shares) | 86.7M shares | 79.4M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $31.0M | $16.1M | |
| Restricted cash | $264.0K | $263.0K | |
| Accounts receivable, net of allowance of $1,066 and $ at December 31, 2025 and December 31, 2024, respectively | $40.0M | $19.8M | |
| Short-term investments | $30.3M | $108.8M | |
| Prepaid expenses and other current assets | $24.7M | $4.7M | |
| Current assets of discontinued operations | $0 | $11.2M | |
| Total current assets | $126.2M | $160.7M | |
| Property and equipment, net | $36.4M | $28.5M | |
| Intangible assets, net | $47.5M | $8.0M | |
| Goodwill | $88.2M | $15.5M | $13.3M |
| Operating right-of-use asset | $3.1M | $2.8M | |
| Other non-current assets | $24.0M | $118.0K | |
| Non current assets of discontinued operations | $0 | $41.0M | |
| Total assets | $325.5M | $256.7M | |
| Accounts payable and accrued expenses | $19.1M | $9.2M | |
| Operating lease liability, current | $652.0K | $682.0K | |
| Current liabilities of discontinued operations | $0 | $12.8M | |
| Total current liabilities | $19.8M | $22.7M | |
| Warrant liability | $1.5M | $5.8M | |
| Operating lease liability, long-term | $2.7M | $2.3M | |
| Deferred tax liability | $348.0K | $0 | |
| Other non-current liabilities | $22.1M | $0 | |
| Non-current liabilities of discontinued operations | $0 | $3.9M | |
| Total liabilities | $46.4M | $34.7M | |
| Preferred stock, $0.0001 par value, 2,000,000 shares authorized; no shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $0 | $0 | |
| Common stock, $0.0001 par value; 400,000,000 authorized; 86,702,183 and 79,419,028 shares issued at December 31, 2025 and December 31, 2024, respectively | $7.0K | $7.0K | |
| Additional paid in capital | $424.6M | $407.1M | |
| Accumulated other comprehensive income | $0 | $1.8M | |
| Accumulated deficit | -$145.6M | -$186.9M | |
| Total stockholders' equity | $279.1M | $221.9M | $234.3M |
| Total liabilities and stockholders' equity | $325.5M | $256.7M | |
| Allowance for credit losses | $1.1M | $0 | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 2.0M shares | 2.0M shares | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 400.0M shares | 400.0M shares | |
| Common stock, shares issued (in shares) | 86.7M shares | 79.4M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net income / (loss) | $41.3M | -$27.3M |
| Gain on sale of business | -$57.0M | $0 |
| Depreciation and amortization | $8.2M | $6.0M |
| Stock-based compensation | $17.8M | $19.9M |
| Change in fair value of warrant liabilities | -$4.3M | $850.0K |
| Change in fair value of assets and other liabilities | $1.0M | $0 |
| Excess of lease liability over operating right-of-use assets | $0 | -$123.0K |
| Transaction costs paid related to sale of business | -$7.4M | $0 |
| Gain on lease modification | $0 | -$622.0K |
| Acquisition consideration allocated to seller transaction expenses | -$44.3M | $0 |
| Impairment of intangible assets | $0 | $5.8M |
| Impairment of property and equipment | $1.7M | $0 |
| Realized loss from sale of short-term investments | $5.2M | $0 |
| Realized foreign exchange gain | -$798.0K | $0 |
| Accretion of interest income on held-to-maturity securities | -$2.2M | -$4.0M |
| Deferred tax expense (benefit) | $432.0K | -$255.0K |
| Other | $471.0K | $323.0K |
| Prepaid expenses and other current assets | -$1.7M | $6.4M |
| Accounts receivable | -$12.0M | -$998.0K |
| Other non-current assets | $666.0K | -$70.0K |
| Operating right-of-use assets/lease liabilities | -$88.0K | $164.0K |
| Accounts payable and accrued expenses | $2.4M | -$8.3M |
| Deferred revenue | $1.7M | -$119.0K |
| Net cash used in operating activities | -$48.9M | -$2.5M |
| Acquisitions, net of cash acquired | -$66.5M | -$2.2M |
| Cash transfer from sale of business | -$2.8M | $0 |
| Capitalized software development costs | -$1.4M | -$2.1M |
| Purchase of property and equipment, net of proceeds from disposal | -$9.6M | -$30.9M |
| Purchase of held-to-maturity investments | -$146.3M | -$143.3M |
| Proceeds from maturities of held-to-maturity investments | $226.2M | $177.4M |
| Proceeds from sale of short-term investments | $70.2M | $0 |
| Net cash provided by / (used in) investing activities (includes discontinued operations; see Note 5) | $69.8M | -$1.0M |
| Proceeds from the exercise of common stock options | $193.0K | $168.0K |
| Taxes paid related to net share settlement of equity awards | -$9.1M | -$5.7M |
| Repurchase and retirement of common stock | $0 | -$244.0K |
| Net cash used in financing activities | -$8.9M | -$5.8M |
| Effect of foreign exchange rate changes on cash balances | -$339.0K | -$80.0K |
| Net increase (decrease) in cash and cash equivalents and restricted cash | $11.6M | -$9.4M |
| Income Taxes paid | $87.0K | $0 |
| Common stock received for sale of business | $75.4M | $0 |
| Contingent consideration and indemnity holdback receivable from sale of business in prepaids and other current assets and other non-current assets, respectively | $36.4M | $0 |
| New leases under ASC 842 entered into during the period | $1.6M | $8.4M |
| Contingent consideration in accounts payable and accrued expenses and other non-current liabilities | $9.1M | $0 |
| Common stock issued for acquisition | $8.4M | $0 |
| Purchases of property and equipment and capitalized software in accounts payable and accrued expenses | $128.0K | $375.0K |
| "Modification of existing right-of-use assets (""ROU"") and lease liability" | $0 | $12.7M |
| Derecognition of ROU assets and lease liability | $0 | -$6.4M |
| Common stock issued for settlement of earn-out previously in accounts payable and accrued expenses | $0 | $3.0M |
No quarter-by-quarter statement was filed.
Corporate structure
Strata Critical Medical, Inc. sits at the top of its group. 5 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Strata Critical Medical, Inc.
- Third Point LLC Filed SCHEDULE 13D on Strata Critical Medical, Inc., latest Oct 15, 2026 (3 filings since Aug 11, 2025)
- Steele ExpCo Holdings, LLC Filed SCHEDULE 13G/A on Strata Critical Medical, Inc., latest Aug 20, 2026 (3 filings since Jan 24, 2022)
- ARK Investment Management LLC Filed SCHEDULE 13G/A on Strata Critical Medical, Inc., latest Jul 8, 2026 (8 filings since Nov 9, 2021)
- Northern Right Capital Management, L.P. Filed SCHEDULE 13G on Strata Critical Medical, Inc., latest Jun 17, 2026
- Velibor Krstic Filed SCHEDULE 13D/A on Strata Critical Medical, Inc., latest May 8, 2026 (4 filings since Apr 7, 2026)
- BlackRock Filed SCHEDULE 13G on Strata Critical Medical, Inc., latest Jan 21, 2026 (6 filings since Feb 3, 2023)
- Amova Asset Management Americas, Inc. Filed SC 13G/A on Strata Critical Medical, Inc., latest Nov 8, 2024 (4 filings since Feb 14, 2022)
- Sumitomo Mitsui Trust Group Filed SC 13G/A on Strata Critical Medical, Inc., latest Nov 5, 2024 (4 filings since Feb 4, 2022)
- DigitalBridge Filed SC 13D on Strata Critical Medical, Inc., latest Jul 12, 2024
- HG Vora Capital Management, LLC Filed SC 13G/A on Strata Critical Medical, Inc., latest Jun 9, 2023 (2 filings since Feb 14, 2023)
- RB LIFT LLC Filed SC 13D/A on Strata Critical Medical, Inc., latest Mar 31, 2023 (2 filings since Jan 19, 2023)
- Goldman Sachs Filed SC 13G/A on Strata Critical Medical, Inc., latest Feb 13, 2023 (2 filings since Feb 2, 2022)
- Strata Critical Medical, Inc. New York, New York
- Keystone Perfusion Services LLC Subsidiary · Pennsylvania, United States
- Strata Critical, Inc. Subsidiary · Delaware, United States
- Trinity Air Medical, LLC Subsidiary · Arizona, United States
- Trinity Medical Intermediate, Inc. Subsidiary · Delaware, United States
Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Strata Critical Medical, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $42.7M5 Dec 31, 2025 | $31.0M5 Dec 31, 2024 | +37.7% |
| Accumulated depreciation | $6.3M5 Dec 31, 2025 | $2.6M5 Dec 31, 2024 | +144.2% |
| Property and equipment, net | $36.4M5 Dec 31, 2025 | $28.5M5 Dec 31, 2024 | +28.0% |
| Operating-lease assets (leased space) | $3.1M5 Dec 31, 2025 | $2.8M5 Dec 31, 2024 | +9.7% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $31.0M5 Dec 31, 2025 | $18.4M5 Dec 31, 2024 | +68.5% |
| Marketable securities, current | $30.3M5 Dec 31, 2025 | $108.8M5 Dec 31, 2024 | −72.2% |
| Debt securities held to maturity | $30.3M5 Dec 31, 2025 | $108.8M5 Dec 31, 2024 | −72.2% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $88.2M5 Dec 31, 2025 | $15.5M5 Dec 31, 2024 | +467.6% |
| Intangible assets, net (excluding goodwill) | $47.5M5 Dec 31, 2025 | $8.0M5 Dec 31, 2024 | +496.5% |
| Finite-lived intangibles, gross | $54.5M5 Dec 31, 2025 | $12.3M5 Dec 31, 2024 | +341.9% |
| Accumulated amortization | $7.0M5 Dec 31, 2025 | $4.4M5 Dec 31, 2024 | +59.7% |
| Finite-lived intangibles, net | $47.5M5 Dec 31, 2025 | $8.0M5 Dec 31, 2024 | +496.5% |
Properties, in its own words
Offices and Operating Locations
Our corporate headquarters is located in New York, New York. This facility supports our executive leadership and centralized corporate functions, including for technology, finance and accounting, legal, and other administrative functions.
The rest of Item 2
Our operations center is in Chandler, Arizona, which is staffed 24/7/365 to support coordination of trips in our Logistics segment, clinical services, and other operational and administrative functions. Managers and executives in our Logistics business work from our operations center in Arizona except for those in Organ Placement, who operate remotely.
Our Clinical segment operates with a distributed workforce. Staff and equipment are typically based at or near the hospitals and Organ Procurement Organizations they primarily support, with certain transplant clinical staff and equipment positioned at air logistics hubs to enable more efficient deployment. Managers and executives in our Clinical business work remotely, enabling them to frequently engage with and support our geographically dispersed workforce.
Aircraft Assets
As of December 31, 2025, we owned nine Hawker 800 series midsize jets that support Strata’s Logistics segment. Additionally, in 2024, we purchased a tenth aircraft and assumed full operational control, though legal title remains with the seller, M&N, who also operates the aircraft. The purchase price has been fully paid and is held as a deposit until title transfer to Strata. This aircraft has been in service for Strata since late September 2024.
Our fleet has an average age of 27 years and an average seating capacity of 8 seats per aircraft. Our fleet is painted in white with varying stripe colors, and all aircraft will display the “Strata” logo in black or blue by the end of 2026. These aircraft are operated and maintained by third-party service providers under Strata's oversight and are strategically based across key airports in Bedford, Massachusetts; Teterboro, New Jersey; Scottsdale, Arizona; Madison, Wisconsin; and Denver, Colorado to support our operations efficiently. All aircraft undergo routine maintenance, inspection and certification processes, which may, at times, require temporary relocation to third-party maintenance facilities. All aircraft are maintained in accordance with FAA regulations and industry standards to ensure operational safety and reliability.
In addition to the ten aircraft discussed above, Strata has contractual relationships with various aircraft operators to provide aircraft service under CPAs, some of which contain embedded aircraft leases. Under these CPAs, the Company pays the operator contractually agreed fees (carrier costs) for operating these flights. The fees are generally based on fixed hourly rates multiplied by hours flown.
Item 2 of the 10-K filed Mar 3, 2026.4
Leadership
Who has led Strata Critical Medical, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
- Chief executive officerMelissa M. Tomkiel Sep 12, 2025 to Dec 4, 202513
- Chief executive officerWilliam A. Heyburn Sep 12, 2025 to Dec 4, 202514
- Chief executive officerLouis R. Verdetto Dec 4, 2025 to now15
- Chief executive officerScott M. Wunsch Jun 25, 2024 to Sep 12, 202516
- Chief executive officerSeth J. Bacon Sep 14, 2023 to Jun 17, 202417
- Chief executive officerEric Affeldt Sep 12, 2019 to Sep 12, 201918
- PresidentMelissa M. Tomkiel May 17, 2021 to now19
- Chief financial officerWilliam A. Heyburn May 17, 2021 to now20
Board members and other officers (18)
- Chief Technology OfficerAnatoli Arkhipenko Apr 21, 2022 to Nov 14, 202221
- Chief Accounting OfficerAmir Cohen May 17, 2021 to now22
- Chief Technology OfficerBrandon A. Keene May 17, 2021 to Nov 21, 202223
- Chief Investment OfficerMichael Mohapp Sep 12, 2019 to Sep 12, 201924
- Board memberMelissa M. Tomkiel Sep 12, 2025 to now13
- Board memberWilliam A. Heyburn Sep 12, 2025 to now14
- Board memberAndrew Lauck Mar 31, 2023 to now25
- Board memberJohn Borthwick Apr 6, 2023 to now26
- Board memberDavid Zaslav May 17, 2021 to Sep 24, 202127
- Board memberJane C. Garvey May 17, 2021 to Aug 9, 202328
- Board memberSusan M. Lyne May 17, 2021 to now29
- Board memberReginald Love Sep 27, 2021 to now30
- Board memberBrian C. Witherow Sep 12, 2019 to Sep 12, 201931
- Board memberEdward M. Philip Sep 12, 2019 to now32
- Board memberEric Affeldt Sep 12, 2019 to now18
- Board memberMartin J. Newburger Sep 12, 2019 to Sep 12, 201933
- Board memberRafael Pastor Sep 12, 2019 to Sep 12, 201934
- General counselMelissa M. Tomkiel May 17, 2021 to now19
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- Keystone Perfusion Services LLC Pennsylvania3
- Strata Critical, Inc. Delaware3
- Trinity Air Medical, LLC Arizona3
- Trinity Medical Intermediate, Inc. Delaware3
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
Timeline
- Aug 4, 20268-K Results of operations35
- Jun 3, 20268-K Shareholder vote36
- May 6, 20268-K Results of operations37
- Mar 3, 20268-K Results of operations38
- Feb 5, 20268-K Entered a material agreement; Regulation FD disclosure39
- Dec 4, 2025New chief executive Louis R. Verdetto becomes CEO15
- Dec 3, 20258-K Executive or director change; Regulation FD disclosure40
- Dec 2, 20258-K Completed an acquisition or sale41
- Nov 10, 20258-K Results of operations42
- Sep 16, 20258-K Entered a material agreement; Completed an acquisition or sale; Unregistered sale of shares43
- Sep 12, 2025New chief executive William A. Heyburn becomes CEO14
- Sep 12, 2025New chief executive Melissa M. Tomkiel becomes CEO13
- Sep 12, 20258-K Shareholder vote44
- Aug 29, 20258-K Executive or director change45
- Aug 29, 20258-K Entered a material agreement; Completed an acquisition or sale; Executive or director change46
- Jun 25, 2024New chief executive Scott M. Wunsch becomes CEO16
- Sep 14, 2023New chief executive Seth J. Bacon becomes CEO17
- Sep 12, 2019New chief executive Eric Affeldt becomes CEO18
Calendar
Coming up
- Nov 9, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.06) a share, on Nov 10, 2025.47
When it reported results
- Aug 4, 2026Reported quarterly or annual results35
- May 6, 2026Reported quarterly or annual results37
- Mar 3, 2026Reported quarterly or annual results38
- Nov 10, 2025Reported quarterly or annual results42
- Aug 5, 2025Reported quarterly or annual results48
- May 12, 2025Reported quarterly or annual results49
- Mar 13, 2025Reported quarterly or annual results50
- Nov 12, 2024Reported quarterly or annual results51
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
436 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 43 major events, 263 insider forms, 42 large holders, 68 other. The latest 20:
- Oct 15, 2026SCHEDULE 13D EDGAR
- Oct 2, 2026144 EDGAR
- Sep 25, 20264 EDGAR
- Sep 25, 20264 EDGAR
- Sep 10, 20264 EDGAR
- Sep 10, 20264 EDGAR
- Sep 10, 20264 EDGAR
- Sep 10, 20264 EDGAR
- Sep 10, 20264 EDGAR
- Aug 20, 2026SCHEDULE 13G/A EDGAR
- Aug 13, 20264 EDGAR
- Aug 4, 202610-Q EDGAR
- Aug 4, 20268-K EDGAR
- Aug 3, 20264 EDGAR
- Aug 3, 20264 EDGAR
- Aug 3, 20264 EDGAR
- Aug 3, 20264 EDGAR
- Aug 3, 20264 EDGAR
- Aug 3, 20264 EDGAR
- Aug 3, 20264 EDGAR
The 436 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
129 open-market trades by officers, directors and large owners since October 2021: 5 buys and 124 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 10, 2026 | Love ReginaldDirector | Sale | 5,091 | $5.75 | $29.3K | Form 4 |
| Jun 8, 2026 | Heyburn William A.Co-CEO and CFO | Sale | 31,671 | $5.87 | $185.9K | Form 4 |
| Jun 8, 2026 | Cohen AmirChief Accounting Officer | Sale | 4,655 | $5.87 | $27.3K | Form 4 |
| Jun 8, 2026 | Tomkiel Melissa M.Co-CEO and General Counsel | Sale | 29,730 | $5.87 | $174.5K | Form 4 |
| Jun 8, 2026 | Wunsch Scott MCEO, Logistics | Sale | 5,550 | $5.87 | $32.6K | Form 4 |
| May 22, 2026 | Cohen AmirChief Accounting Officer | Sale | 40,575 | $5.91 | $239.8K | Form 4 |
| May 21, 2026 | Cohen AmirChief Accounting Officer | Sale | 10,300 | $5.79 | $59.6K | Form 4 |
| May 11, 2026 | Cohen AmirChief Accounting Officer | Sale | 14,306 | $5.79 | $82.8K | Form 4 |
| Dec 9, 2025 | Heyburn William A.Co-CEO and CFO | Buy | 17,000 | $4.47 | $76.0K | Form 4 |
| Dec 5, 2025 | LAUCK ANDREWDirector | Buy | 5,000 | $4.37 | $21.9K | Form 4 |
| Nov 20, 2025 | Love ReginaldDirector | Sale | 11,000 | $4.37 | $48.1K | Form 4 |
| Nov 19, 2025 | Love ReginaldDirector | Sale | 11,000 | $4.31 | $47.4K | Form 4 |
| Aug 4, 2025 | Tomkiel Melissa M.Co-CEO and General Counsel | Sale | 47,995 | $4.94 | $237.1K | Form 4 |
| Aug 4, 2025 | Heyburn William A.Co-CEO and CFO | Sale | 46,918 | $4.94 | $231.8K | Form 4 |
| Jun 9, 2025 | Tomkiel Melissa M.Co-CEO and General Counsel | Sale | 100,000 | $4.08 | $408.0K | Form 4 |
| Jun 9, 2025 | Heyburn William A.Co-CEO and CFO | Sale | 100,000 | $4.07 | $407.0K | Form 4 |
| Jan 7, 2025 | Heyburn William A.Co-CEO and CFO | Sale | 900 | $5.00 | $4.5K | Form 4 |
| Jan 6, 2025 | Heyburn William A.Co-CEO and CFO | Sale | 103,670 | $5.02 | $520.4K | Form 4 |
| Dec 13, 2024 | Love ReginaldDirector | Sale | 5,091 | $4.05 | $20.6K | Form 4 |
| Dec 13, 2024 | Borthwick JohnDirector | Sale | 78,291 | $4.00 | $313.2K | Form 4 |
All 129 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Third Point LLCSCHEDULE 13D, 3 filings Aug 11, 2025 to Oct 15, 202652
- Steele ExpCo Holdings, LLCSCHEDULE 13G/A, 3 filings Jan 24, 2022 to Aug 20, 202653
- ARK Investment Management LLCSCHEDULE 13G/A, 8 filings Nov 9, 2021 to Jul 8, 202654
- Northern Right Capital Management, L.P.SCHEDULE 13G, 1 filing Jun 17, 202655
- Velibor KrsticSCHEDULE 13D/A, 4 filings Apr 7, 2026 to May 8, 202656
- BlackRockSCHEDULE 13G, 6 filings Feb 3, 2023 to Jan 21, 202657
- Amova Asset Management Americas, Inc.SC 13G/A, 4 filings Feb 14, 2022 to Nov 8, 202458
- Sumitomo Mitsui Trust GroupSC 13G/A, 4 filings Feb 4, 2022 to Nov 5, 202459
- DigitalBridgeSC 13D, 1 filing Jul 12, 202460
- HG Vora Capital Management, LLCSC 13G/A, 2 filings Feb 14, 2023 to Jun 9, 202361
- RB LIFT LLCSC 13D/A, 2 filings Jan 19, 2023 to Mar 31, 202362
- Goldman SachsSC 13G/A, 2 filings Feb 2, 2022 to Feb 13, 202363
- FMR LLCSC 13G/A, 1 filing Feb 9, 202264
- Magnetar Financial LLCSC 13G/A, 1 filing Jan 7, 202265
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Melissa M. TomkielCo-Chief Executive Officer and General Counsel | $533.3K | $5.6M66 | |
| 2025 | William A. HeyburnCo-Chief Executive Officer and Chief Financial Officer | $516.7K | $5.3M66 | |
| 2025 | Robert S. WiesenthalNon-Executive Chairman of the Board and Former Chief Executive Officer | $500.0K | $5.1M66 | |
| 2025 | Scott M. WunschCEO, Logistics | $347.7K | $2.4M66 | |
| 2025 | Amir M. CohenChief Accounting Officer | $375.0K | $897.9K66 | |
| 2024 | Robert S. WiesenthalNon-Executive Chairman of the Board and Former Chief Executive Officer | $750.0K | $9.6M66 | |
| 2024 | Melissa M. TomkielCo-Chief Executive Officer and General Counsel | $525.0K | $6.1M66 | |
| 2024 | William A. HeyburnCo-Chief Executive Officer and Chief Financial Officer | $500.0K | $5.4M66 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Strata Critical Medical, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARStrata Critical Medical, Inc.1
- CIK0001779128
- Employer ID (EIN)84-18903814
- Filer statusAccelerated filer not an emerging growth company; a smaller reporting company; not a shell company4
- Incorporated inDelaware4
- Fiscal year endsDecember 311
- Industry code (SIC)8000 Services-Health Services1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business address666 Third Avenue, 25Th Floor, New York, NY 100171
- Phone212-967-10091
- Shares outstanding88,466,806 as of Jul 28, 202612
- Public float$263.9M as of Jun 30, 20254
- AuditorDeloitte & Touche LLP, New York, New York PCAOB ID 34; it also attests to the company’s internal control over financial reporting4
- On EDGAR sinceJun 26, 20191
- Filings571 in all: 4 (262), 8-K (57), 144 (44), SC 13G/A (28), 3 (27), 10-Q (20), 425 (19), SC 13G (14)1
All 39 form types
424B3 (10), 4/A (9), 10-K (7), CORRESP (7), SCHEDULE 13G/A (7), DEF 14A (5), DEFA14A (5), EFFECT (5), 8-K/A (4), SC 13D (4), SCHEDULE 13G (4), UPLOAD (4), S-4/A (3), S-8 (3), SCHEDULE 13D/A (3), 25-NSE (2), POS AM (2), S-1 (2), SCHEDULE 13D (2), 10-K/A (1), 10-QT (1), 3/A (1), 424B4 (1), 5 (1), 8-A12B (1), CERT (1), DRS (1), NT 10-Q (1), S-1/A (1), S-4 (1), SC 13D/A (1)
- Latest filingsAnnual report (10-K) Mar 3, 2026
Quarterly report (10-Q) Aug 4, 2026
Proxy statement (DEF 14A) Apr 14, 2026
Latest 8-K (8-K) Aug 4, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, $0.0001 par value per share | SRTA | The Nasdaq Stock Market |
| Warrants, each exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share | SRTAW | The Nasdaq Stock Market |
From the cover page of the 10-K filed Mar 3, 2026 (Section 12(b) of the Exchange Act).4
Risk factors and legal proceedings
The risks Strata Critical Medical, Inc. names in Item 1A of its 10-K filed Mar 3, 2026: 57 risks under these headings, as written.4
- Risks Related to Our Business and Growth Strategy
- We have incurred significant losses since inception and may continue to incur net losses from continuing operations in the future, and we may not be able to achieve or maintain profitability.
- Any inability to realize the anticipated benefits of the sale of the Passenger business or acquisition of Keystone could negatively impact our stock price and our business and financial results.
- If we experience harm to our reputation and brand, our business, financial condition, and results of operations could be adversely affected.
- We provide clinical services to our customers and perfusion staffing services to hospitals and health systems. We may be subject to negative publicity and reputational damage related to the provision of such services, as well as litigation, claims, investigations, and other proceedings, which could result in actions including substantial judgments, settlement costs, uninsured or underinsured liabilities, and other adverse consequences.
- Any failure to offer high-quality customer support may harm our relationships with Medical Customers and could adversely affect our reputation, brand, business, financial condition, and results of operations.
- Our reliance on contractual relationships with certain transplant centers, hospitals, Organ Procurement Organizations and other strategic alliances could adversely affect our business, financial condition and results of operations.
- Our growth may depend on the adoption and effective utilization of integrated clinical and logistics workflows by our Medical Customers, and failure to achieve such adoption could adversely affect our business, financial condition, and results of operations.
- The organ transportation and clinical services markets in which we operate are highly competitive, and increased competition could adversely affect our business, financial condition and results of operations.
- Our business depends on the availability of organ donors and viable donor organs, which are influenced by factors beyond our control, and any decrease in the availability or utilization of viable donor organs could have a material adverse effect on demand for our services and results of operations.
- Reimbursement and funding for medical transport services may be insufficient, adversely affecting our revenue and profitability.
- The transport of organs involves numerous risks and delivery failures could expose us to liability and have a material adverse effect on our business, financial condition, results of operations, and reputation.
The other 46 risks
- Risks associated with our ground transportation operations could adversely affect our business and financial results.
- Advancements in technology could make ground or commercial air transport of organs more viable, reducing the need for our private air transportation services.
- Operation of aircraft involves a degree of inherent risk. We could suffer losses and adverse publicity stemming from any accident involving small aircraft, helicopters, or charter flights and, in particular, from any accident involving our third-party aircraft operators.
- We are subject to risks associated with climate change, including regulatory developments and the potential increased impacts of severe weather events on our operations and infrastructure.
- Terrorist attacks, geopolitical conflict or security events may adversely affect our business, financial condition and results of operations.
- Our business is dependent on the availability of aircraft fuel. Continued disruptions in the supply or cost of aircraft fuel could adversely affect our operations, financial conditions, and results of operations.
- We may require substantial additional funding to finance our operations, but adequate additional financing may not be available when we need it, on acceptable terms, or at all.
- Restrictive covenants in our Credit Agreement may restrict our ability to pursue our business strategies and we may incur substantial additional indebtedness in the future.
- As part of our growth strategy, we may pursue future acquisitions, partnerships, or strategic transactions that could disrupt our business and adversely affect our financial condition and results of operations.
- We may be unable to manage our future growth effectively, which could make it difficult to execute our business strategy.
- Our insurance, or that of our third-party aircraft operators, may become too difficult or expensive for us or them to obtain. Increases in insurance costs or reductions in insurance coverage may materially and adversely impact our results of operations and financial position.
- We are highly dependent on our senior management team and other highly skilled personnel. If we are not successful in attracting or retaining highly qualified personnel, we may not be able to successfully implement our business strategy.
- Employment-related claims or workforce litigation could result in significant costs and operational disruption.
- Our company culture has contributed to our success, and if we cannot maintain this culture as we grow, our business could be harmed.
- Our financial results may fluctuate from quarter to quarter, which makes our results difficult to predict and may cause our results to fall short of expectations.
- We may purchase additional aircraft in the future.
- If we choose to operate some aircraft directly in the future, versus utilizing a third-party, we would be subject to additional risks.
- We are especially vulnerable to delays, cancellations, or flight rescheduling, as we rely on maintaining efficient aircraft utilization to manage direct costs associated with third-party operators.
- The provision of healthcare services is a heavily regulated industry and our medical logistics and clinical services may be impacted by regulatory changes, legislative reforms, and civil or criminal enforcement actions.
- Due to the effects of discontinued operations for the Passenger business, our historical financial results may not be comparable to current or future results.
- Risks Related to Our Dependence on Third-Party Providers
- We rely on our third-party contractors to provide and operate aircraft. If such third-party contractors do not perform adequately or terminate their relationships with us, our costs may increase and our business, financial condition, and results of operations could be adversely affected.
- If our third-party aircraft operators are unable to match our growth in demand or we are unable to add additional third-party aircraft operators to our network to meet demand, our costs may increase and our business, financial condition, and results of operations could be adversely affected.
- If we encounter problems with any of our third-party aircraft operators or third-party service providers, such as workforce disruptions or operational interruptions, our operations could be adversely affected by a resulting decline in revenue or negative public perception about our services.
- Illegal, improper, or otherwise inappropriate operation of Strata-owned or Strata-branded aircraft by our third-party aircraft operators, regardless of whether they are operating aircraft on our behalf, could harm our reputation, business, brand, financial condition, and results of operations.
- We rely on third-party web service providers to support our technology systems, and any disruption of or interference with our use of these services could adversely affect our business, financial condition, and results of operations.
- Risks Related to Intellectual Property, Cybersecurity, Information Technology and Data Management Practices
- System failures, defects, errors, or vulnerabilities in our website, applications, backend systems, or other technology systems or those of third-party technology providers could harm our reputation and brand and adversely impact our business, financial condition, and results of operations.
- We rely on our information technology systems to manage numerous aspects of our business. A cyber-based attack of these systems could disrupt our ability to deliver services to our customers and could lead to increased overhead costs, decreased sales, and harm to our reputation.
- If we fail to adequately protect our proprietary intellectual property rights, our competitive position could be impaired and we may lose market share, generate reduced revenue, and incur costly litigation to protect our rights.
- We use open-source software in connection with our platform, which may pose risks to our intellectual property.
- Legal and Regulatory Risks Related to Our Business
- We could be subject to litigation or regulatory investigations, which may be expensive and could divert management attention.
- Failure to comply with laws and regulations relating to privacy, data protection, cybersecurity, healthcare information, and consumer protection, or the expansion of current laws and regulations or the enactment of new laws or regulations in these areas, could adversely affect our business and our financial condition.
- Failure to comply with applicable healthcare, privacy, security and data protection laws and regulations could result in a material breach of contract with one or more of our Medical Customers, subject us to enforcement actions and adversely affect our business and our financial condition.
- Environmental regulation and liabilities, including new or developing laws and regulations, may increase our costs of operations and adversely affect us.
- Risks Related to Ownership of Our Securities and Being a Public Company
- We have in the past and may in the future identify material weaknesses in our internal control over financial reporting.
- If we fail to maintain an effective system of disclosure controls and internal control over financial reporting, our ability to produce timely and accurate financial statements or comply with applicable regulations could be impaired.
- Our Warrants are accounted for as derivative liabilities and are recorded at fair value with changes in fair value for each period reported in earnings, which may have an adverse effect on the market price of our common stock.
- The market price of our securities may change significantly, and you could lose all or part of your investment as a result.
- There is no guarantee that the Warrants will ever be in the money, and they may expire worthless.
- We may redeem unexpired Warrants held by former EIC stockholders prior to their exercise at a time that is disadvantageous to those stockholders, thereby making such Warrants worthless.
- We do not expect to declare any dividends in the foreseeable future.
- We may issue additional shares of common stock or other equity securities without your approval, which would dilute your ownership interest in us and may depress the market price of our common stock.
- Provisions in our charter and Delaware law may inhibit a takeover of us, which could limit the price investors might be willing to pay in the future for our common stock and could entrench management.
- Our Certificate of Incorporation designates the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings and the federal district courts as the sole and exclusive forum for other types of actions and proceedings, in each case, that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain what such stockholders believe to be a favorable judicial forum for disputes with the Company or our directors, officers, or other employees.
- Future sales, or the perception of future sales, by us or our stockholders in the public market could cause the market price for the common stock to decline.
Legal proceedings
In the opinion of management, other than as described below, we are not involved in any claims, legal actions, or regulatory proceedings as of December 31, 2025, the ultimate disposition of which would have a material adverse effect on our consolidated financial position, results of operations, or cash flows.
In February 2024, two putative class action lawsuits relating to the acquisition of Blade Urban Air Mobility, Inc. (“Old Blade”) were filed in the Delaware Court of Chancery. On April 16, 2024, these cases were consolidated under the caption Drulias et al. v. Affeldt, et al., C.A. No. 2024-0161-SG (Del. Ch.) (“Drulias”). Plaintiffs assert claims for breach of fiduciary duty and unjust enrichment claims against the former directors of Experience Investment Corp. (“EIC” and such directors, the “EIC Directors”), the former officers of EIC, and Experience Sponsor LLC (“Sponsor”), and aiding and abetting breach of fiduciary duty claim against Sponsor. The operative complaint alleges, amongst other things, that the proxy statement related to the acquisition of Old Blade insufficiently disclosed EIC’s cash position, Old Blade’s value prospects and risks, and information related to Old Blade’s chief executive officer, who was also the Company’s former chief executive officer. The consolidated complaints seek, among other things, damages and attorneys’ fees and costs. Litigation is ongoing. On December 16, 2025, the parties entered into a Stipulation of Settlement to fully resolve the matter, subject to certain customary conditions including Court approval. The Company made the settlement payment in December 2025.
The opening of Item 3, Legal Proceedings.4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19SEC EDGARMelissa M. Tomkiel, President
- 20
- 21
- 22SEC EDGARAmir Cohen, Chief Accounting Officer
- 23
- 24
- 25SEC EDGARAndrew Lauck, Board member
- 26SEC EDGARJohn Borthwick, Board member
- 27SEC EDGARDavid Zaslav, Board member
- 28SEC EDGARJane C. Garvey, Board member
- 29SEC EDGARSusan M. Lyne, Board member
- 30SEC EDGARReginald Love, Board member
- 31SEC EDGARBrian C. Witherow, Board member
- 32SEC EDGAREdward M. Philip, Board member
- 33SEC EDGARMartin J. Newburger, Board member
- 34SEC EDGARRafael Pastor, Board member
- 35SEC EDGARResults of operations
- 36SEC EDGARShareholder vote
- 37SEC EDGARResults of operations
- 38SEC EDGARResults of operations
- 39
- 40
- 41SEC EDGARCompleted an acquisition or sale
- 42SEC EDGARResults of operations
- 43
- 44SEC EDGARShareholder vote
- 45SEC EDGARExecutive or director change
- 46
- 47NasdaqNasdaq calendar
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66